A review of the safety of drugs for Crohns’ disease has found that newer biologics such as vedolizumab and ustekinumab appear to be safer options than anti-TNF agents. The review said adverse events associated with vedolizumab appear to be mainly upper respiratory tract infections and nasopharyngitis with no serious risk of opportunistic infections or malignancy. ...
Already a member?
Enter your email to keep reading.